Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOWLNASDAQ:LRMRNASDAQ:NBTXNASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOWLWerewolf Therapeutics$1.20-4.4%$1.10$0.60▼$4.18$56.09M0.66440,228 shs257,257 shsLRMRLarimar Therapeutics$3.25+8.7%$2.37$1.61▼$11.20$191.44M0.79837,857 shs2.03 million shsNBTXNanobiotix$4.54+3.0%$3.96$2.76▼$6.00$207.86M0.3615,530 shs997 shsPBYIPuma Biotechnology$3.31-1.5%$3.25$2.23▼$4.13$166.76M1.29440,578 shs208,950 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOWLWerewolf Therapeutics-4.40%-3.63%+3.91%+11.68%-48.93%LRMRLarimar Therapeutics+8.70%+18.61%+73.80%+36.84%-53.80%NBTXNanobiotix+2.97%+3.68%+19.53%+25.10%-6.95%PBYIPuma Biotechnology-1.49%-2.65%+2.48%+5.08%+11.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOWLWerewolf Therapeutics3.1441 of 5 stars3.53.00.00.00.65.00.6LRMRLarimar Therapeutics2.4363 of 5 stars3.63.00.00.02.31.70.0NBTXNanobiotix2.2514 of 5 stars3.35.00.00.01.10.00.6PBYIPuma Biotechnology4.2419 of 5 stars3.52.00.00.02.74.23.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOWLWerewolf Therapeutics 3.00Buy$8.33597.35% UpsideLRMRLarimar Therapeutics 3.11Buy$18.50469.23% UpsideNBTXNanobiotix 2.50Moderate Buy$8.0076.17% UpsidePBYIPuma Biotechnology 3.00Buy$7.00111.48% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, LRMR, NBTX, and PBYI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.006/24/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.005/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.004/4/2025NBTXNanobiotixGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOWLWerewolf Therapeutics$1.88M28.52N/AN/A$1.65 per share0.72LRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ANBTXNanobiotix$39.18M5.46N/AN/A($1.51) per share-3.01PBYIPuma Biotechnology$230.50M0.71$0.84 per share3.94$1.88 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOWLWerewolf Therapeutics-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/AN/APBYIPuma Biotechnology$30.28M$0.774.308.71N/A16.37%49.35%18.25%7/30/2025 (Estimated)Latest HOWL, LRMR, NBTX, and PBYI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOWLWerewolf Therapeutics0.468.098.09LRMRLarimar TherapeuticsN/A7.487.48NBTXNanobiotixN/A1.041.04PBYIPuma Biotechnology0.111.531.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOWLWerewolf Therapeutics64.84%LRMRLarimar Therapeutics91.92%NBTXNanobiotix38.81%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipHOWLWerewolf Therapeutics23.60%LRMRLarimar Therapeutics4.50%NBTXNanobiotix3.45%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOWLWerewolf Therapeutics4044.87 million34.28 millionOptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableHOWL, LRMR, NBTX, and PBYI HeadlinesRecent News About These CompaniesPuma Biotechnology: Updated Timelines And A Resurgence In SentimentJune 25 at 11:31 AM | seekingalpha.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a BargainJune 24 at 9:50 AM | zacks.comPuma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?June 24 at 4:35 AM | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 8,100 Shares of StockJune 18, 2025 | insidertrades.comBrian M. Stuglik Sells 8,100 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 10,800 Shares of StockJune 17, 2025 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval Sells 11,610 SharesJune 17, 2025 | marketbeat.comAlessandra Cesano Sells 12,150 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comJay M. Moyes Sells 22,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comAdrian Senderowicz Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?June 11, 2025 | zacks.comWith 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backingJune 10, 2025 | finance.yahoo.comTwo Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)June 9, 2025 | marketbeat.com78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | businesswire.comMillennium Management LLC Has $5.78 Million Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)May 29, 2025 | marketbeat.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value InvestorsMay 28, 2025 | zacks.comAre Investors Undervaluing Puma Biotechnology (PBYI) Right Now?May 26, 2025 | zacks.comD. E. Shaw & Co. Inc. Buys 165,220 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)May 26, 2025 | marketbeat.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable QualityMay 15, 2025 | uk.finance.yahoo.comDespite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain StockMay 12, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOWL, LRMR, NBTX, and PBYI Company DescriptionsWerewolf Therapeutics NASDAQ:HOWL$1.20 -0.06 (-4.40%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$1.20 +0.00 (+0.42%) As of 06/25/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Larimar Therapeutics NASDAQ:LRMR$3.25 +0.26 (+8.70%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$3.28 +0.03 (+0.92%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Nanobiotix NASDAQ:NBTX$4.54 +0.13 (+2.97%) As of 06/25/2025 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Puma Biotechnology NASDAQ:PBYI$3.31 -0.05 (-1.49%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$3.38 +0.07 (+2.11%) As of 06/25/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
